Prognosis Value of Lymphovascular Invasion in Patients with Invasive Ductal Breast Carcinoma According to Lymph Node Metastasis Status

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2022 Jun 10

PMID 35685958

Authors

Felipe Andres Cordero da Luz

Eduarda da Costa Marinho

Camila Piqui Nascimento

Lara de Andrade Marques

Patricia Ferreira Ribeiro Delfino

Rafael Mathias Antonioli

Rogerio Agenor de Araujo

Marcelo Jose Barbosa Silva

Affiliations

Soon will be listed here.

Abstract

Background: Tumour lymphovascular invasion is not routinely assessed in all pathology services, and whether reporting it quantitatively or qualitatively is the main factor associated with the loss of this prognostic event. This study aimed to analyse the prognostic value of qualitatively reported lymphovascular invasion in patients with invasive breast ductal carcinoma.

Methods: This was a retrospective, single-center study, enrolling a total of 426 patients with invasive ductal carcinoma of the breast with a report of lymphovascular invasion, with a median follow-up of approximately 4.5 years. Kaplan-Meier and Cox regression was performed to obtain the predictive value of lymphovascular invasion. Propensity score matching was performed to reduce bias by standardising factors with significant differential distribution of lymphovascular invasion status.

Results: Lymphovascular invasion was present in 197 (49.2%) patients. Multivariate Cox regression showed that lymphovascular invasion independently increases the risk of death by almost two times (adjusted hazard ratio (HR): 2.045 (1.226-3.406), = 0.006) and the risk of distant metastasis by more than two times (adjusted HR: 2.373 (1.404-4.010), = 0.001). Subgroup analysis after matching by propensity score in adjuvant-only patients showed that the lymphovascular invasion is a factor of increased death in N- patients (adjusted HR: 12.597 (1.624-97.728), = 0.015) and of distant metastasis-free survival in N+ patients (adjusted HR: 4.862 (1.649-14.335), = 0.004) and almost for N- patients (adjusted HR 7.905 (0.969-64.509), = 0.004).

Conclusion: The presence of lymphovascular invasion is a predictor of worse prognosis in patients with invasive ductal carcinoma of the breast, even with metastatic lymph node disease (N1-N3).

Citing Articles

Six Genes Associated with Lymphatic Metastasis in Colon Adenocarcinoma Linked to Prognostic Value and Tumor Immune Cell Infiltration.

Wang B, Yin C, Yang X, Shi H, Zhang Z, Zhou J Evid Based Complement Alternat Med. 2022; 2022:4304361.

PMID: 36072412 PMC: 9444393. DOI: 10.1155/2022/4304361.

References

Wyld L, Reed M, Collins K, Burton M, Lifford K, Edwards A . Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices. Br J Surg. 2021; 108(5):499-510. PMC: 10364907. DOI: 10.1093/bjs/znab005. View

Venet D, Fimereli D, Rothe F, Boeckx B, Maetens M, Majjaj S . Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. EBioMedicine. 2020; 56:102793. PMC: 7281848. DOI: 10.1016/j.ebiom.2020.102793. View

Burstein H, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019; 30(10):1541-1557. DOI: 10.1093/annonc/mdz235. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C . Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol. 2007; 18(10):1632-40. DOI: 10.1093/annonc/mdm268. View

Houvenaeghel G, Cohen M, Classe J, Reyal F, Mazouni C, Chopin N . Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open. 2021; 6(6):100316. PMC: 8645922. DOI: 10.1016/j.esmoop.2021.100316. View

Yildirim E, Berberoglu U . Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg. 2007; 31(2):276-89. DOI: 10.1007/s00268-006-0487-5. View

Mickey R, Greenland S . The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989; 129(1):125-37. DOI: 10.1093/oxfordjournals.aje.a115101. View

Budach W, Bolke E, Kammers K, Gerber P, Nestle-Kramling C, Matuschek C . Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol. 2015; 10:258. PMC: 4687086. DOI: 10.1186/s13014-015-0568-4. View

10.

Chang K, Li G, Kong Y, Shen X, Qu Y, Jia Z . Chemokine Receptors CXCR4 and CXCR7 are Associated with Tumor Aggressiveness and Prognosis in Extramammary Paget Disease. J Cancer. 2017; 8(13):2471-2477. PMC: 5595076. DOI: 10.7150/jca.19127. View

11.

Muller A, Homey B, Soto H, Ge N, CATRON D, Buchanan M . Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-6. DOI: 10.1038/35065016. View

12.

Gujam F, Going J, Mohammed Z, Orange C, Edwards J, McMillan D . Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer. 2014; 14:676. PMC: 4177173. DOI: 10.1186/1471-2407-14-676. View

13.

Lafourcade A, His M, Baglietto L, Boutron-Ruault M, Dossus L, Rondeau V . Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort. BMC Cancer. 2018; 18(1):171. PMC: 5807734. DOI: 10.1186/s12885-018-4076-4. View

14.

da Luz F, da Costa Marinho E, Nascimento C, de Andrade Marques L, Duarte M, Delfino P . The effectiveness of radiotherapy in preventing disease recurrence after breast cancer surgery. Surg Oncol. 2022; 41:101709. DOI: 10.1016/j.suronc.2022.101709. View

15.

Smith B, R Bellon J, Blitzblau R, Freedman G, Haffty B, Hahn C . Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018; 8(3):145-152. DOI: 10.1016/j.prro.2018.01.012. View

16.

Shen S, Zhong S, Wang C, Huang W . Correlation of lymphovascular invasion with clinicopathological factors in invasive breast cancer: a meta-analysis. Int J Clin Exp Med. 2016; 8(10):17789-95. PMC: 4694270. View

17.

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

18.

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

19.

Sopik V, Narod S . The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018; 170(3):647-656. PMC: 6022519. DOI: 10.1007/s10549-018-4796-9. View

20.

Wyld L, Reed M, Morgan J, Collins K, Ward S, Holmes G . Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes and quality of life. Eur J Cancer. 2020; 142:48-62. PMC: 7789991. DOI: 10.1016/j.ejca.2020.10.015. View